首页|Health influence of SARS-CoV-2(COVID-19)on cancer:a review

Health influence of SARS-CoV-2(COVID-19)on cancer:a review

扫码查看
The novel coronavirus,namely,SARS-CoV-2(COVID-19),broke out two years ago and has caused major global health issues.Adequate treatment options are still lacking for the management of COVID-19 viral infections.Many patients afflicted with COVID-19 may range from asymptomatic to severe symptomatic,triggering poor clinical outcomes,morbidity,and mortality.Cancer is one of the leading causes of death worldwide.It is pertinent to re-examine cancer prevalence during the COVID-19 pandemic to prevent mortality and complications.Understanding the impact of SARS-CoV-2 on cancer is key to appropriate healthcare measures for the treatment and prevention of this vulnerable population.Data was acquired from PubMed using key search terms.Additional databases were utilized,such as the Centers for Disease Prevention and Control,American Cancer Society(ACS),and National Cancer Institute(NCI).Cancer patients are more prone to SARS-CoV-2 infection and exhibit poor health outcomes,possibly due to a chronic immunosuppressive state and anticancer therapies.Male sex,older age,and active cancer disease or previous cancer are risk factors for COVID-19 infection,leading to possible severe complications,in-cluding morbidity or mortality.The speculated mechanism for potentially higher mortality or COVID-19 compli-cations is through reduced immune system function and inflammatory processes through cancer disease,anticancer therapy,and active COVID-19 infection.This review includes prostate,breast,ovarian,hematologic,lung,colorectal,esophageal,bladder,pancreatic,cervical,and head and neck cancers.This review should help better maintain the health of cancer patients and direct clinicians for COVID-19 prevention to improve the overall health outcomes.

SARS-CoV-2COVID-19pathologycancertumor

Rachel Parise、Yiran E.Li、Rishi M.Nadar、Sindhu Ramesh、Jun Ren、Manoj Yogish Govindarajulu、Timothy Moore、Muralikrishnan Dhanasekaran

展开 >

Department of Drug Discovery and Development,Auburn University Harrison School of Pharmacy,Walker Building,Auburn,AL 36849,USA

Queen Mary College of Nanchang University,Nanchang 330006,China

Department of Laboratory Medicine and Pathology,University of Washington,Seattle,WA 98195,USA

Department of Cardiology,Zhongshan Hospital Fudan University,Shanghai Institute of Cardiovascular Diseases,Shanghai 200032,China

展开 >

2022

生物化学与生物物理学报(英文版)
中国科学院上海生物化学研究所

生物化学与生物物理学报(英文版)

CSTPCDCSCDSCI
影响因子:0.772
ISSN:1672-9145
年,卷(期):2022.54(10)
  • 70